Drugs / Branch Chain Amino Acid
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT03908255 | Jun 2021 → Dec 2022 | cirrhosis of liver, hepatocellular carcinoma, liver failure | Louisiana State University Health Sciences Center in New Orleans | Withdrawn | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Branch Chain Amino Acid | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03908255 ↗ |
| Known as | BCAA | “Branched-chain amino acid (BCAA) supplementation has been extensively studied for usefulness in liver disease, specifically to treat hepatic encephalopathy to and preserve and...” NCT03908255 ↗ |
| Route | Oral | “consume BCAA supplements beginning two weeks prior to liver directed therapy and continue supplementation for the following 12 months.” NCT03908255 ↗ |